Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s Form 4 filing
Natures Sunshine Products IncNATR · filed Jun 27, 2025
- Accession no.
- 0001140361-25-023976
- Filed
- Jun 27, 2025, 4:27 PM ET
- Trade date
- Jun 27, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $32.7M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd.CIK 0001615258 | 10% Owner |
| Fosun Pharma USA Inc.CIK 0002071437 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 27, 2025 | Common Stock | SSaleDisposed | −2,854,607 | $11.46 | −$32,713,796.22 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.